questionsmedicales.fr
Composés hétérocycliques
Composés hétérocycliques à cycles fusionnés
Composés hétérobicycliques
Quinazolines
Quinazolines : Questions médicales fréquentes
Diagnostic
5
Intoxication
Tests de laboratoire
Analyses sanguines
Analyses urinaires
Surdose
Symptômes neurologiques
Tests de toxicologie
Quinazolines
Efficacité du traitement
Examens d'imagerie
Symptômes
5
Effets secondaires
Éruptions cutanées
Réactions allergiques
Urticaire
Hypersensibilité
Difficultés respiratoires
Système nerveux
Convulsions
Prévention
5
Effets indésirables
Prescriptions médicales
Surveillance
Effets secondaires
Prescriptions
Antécédents médicaux
Informations patient
Interactions médicamenteuses
Traitements
5
Intoxication
Charbon actif
Chimiothérapie
Agents chimiothérapeutiques
Cellules cancéreuses
Inhibition
Antidotes
Traitement symptomatique
Complications
5
Complications
Troubles hépatiques
Problèmes cardiaques
Arythmies
Gestion des complications
Traitement des symptômes
Fonction rénale
Effets néfastes
Complications à long terme
Troubles métaboliques
Facteurs de risque
5
Facteurs de risque
Allergies
Interactions médicamenteuses
Facteurs de risque
Personnes âgées
Sensibilité
Antécédents familiaux
Facteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Quinazolines : Questions médicales les plus fréquentes",
"headline": "Quinazolines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Quinazolines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-08",
"dateModified": "2026-03-28",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Quinazolines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Composés hétérobicycliques",
"url": "https://questionsmedicales.fr/mesh/D006574",
"about": {
"@type": "MedicalCondition",
"name": "Composés hétérobicycliques",
"code": {
"@type": "MedicalCode",
"code": "D006574",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Afatinib",
"alternateName": "Afatinib",
"url": "https://questionsmedicales.fr/mesh/D000077716",
"about": {
"@type": "MedicalCondition",
"name": "Afatinib",
"code": {
"@type": "MedicalCode",
"code": "D000077716",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.786.188"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Chlorhydrate d'erlotinib",
"alternateName": "Erlotinib Hydrochloride",
"url": "https://questionsmedicales.fr/mesh/D000069347",
"about": {
"@type": "MedicalCondition",
"name": "Chlorhydrate d'erlotinib",
"code": {
"@type": "MedicalCode",
"code": "D000069347",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.786.375"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Géfitinib",
"alternateName": "Gefitinib",
"url": "https://questionsmedicales.fr/mesh/D000077156",
"about": {
"@type": "MedicalCondition",
"name": "Géfitinib",
"code": {
"@type": "MedicalCode",
"code": "D000077156",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.786.469"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Lapatinib",
"alternateName": "Lapatinib",
"url": "https://questionsmedicales.fr/mesh/D000077341",
"about": {
"@type": "MedicalCondition",
"name": "Lapatinib",
"code": {
"@type": "MedicalCode",
"code": "D000077341",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.786.516"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Linagliptine",
"alternateName": "Linagliptin",
"url": "https://questionsmedicales.fr/mesh/D000069476",
"about": {
"@type": "MedicalCondition",
"name": "Linagliptine",
"code": {
"@type": "MedicalCode",
"code": "D000069476",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.786.563"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Prazosine",
"alternateName": "Prazosin",
"url": "https://questionsmedicales.fr/mesh/D011224",
"about": {
"@type": "MedicalCondition",
"name": "Prazosine",
"code": {
"@type": "MedicalCode",
"code": "D011224",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.786.750"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Doxazosine",
"alternateName": "Doxazosin",
"url": "https://questionsmedicales.fr/mesh/D017292",
"about": {
"@type": "MedicalCondition",
"name": "Doxazosine",
"code": {
"@type": "MedicalCode",
"code": "D017292",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.786.750.200"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Quinazolinones",
"alternateName": "Quinazolinones",
"url": "https://questionsmedicales.fr/mesh/D052999",
"about": {
"@type": "MedicalCondition",
"name": "Quinazolinones",
"code": {
"@type": "MedicalCode",
"code": "D052999",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.786.830"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Kétansérine",
"alternateName": "Ketanserin",
"url": "https://questionsmedicales.fr/mesh/D007650",
"about": {
"@type": "MedicalCondition",
"name": "Kétansérine",
"code": {
"@type": "MedicalCode",
"code": "D007650",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.786.830.333"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Méthaqualone",
"alternateName": "Methaqualone",
"url": "https://questionsmedicales.fr/mesh/D008702",
"about": {
"@type": "MedicalCondition",
"name": "Méthaqualone",
"code": {
"@type": "MedicalCode",
"code": "D008702",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.786.830.666"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Métolazone",
"alternateName": "Metolazone",
"url": "https://questionsmedicales.fr/mesh/D008788",
"about": {
"@type": "MedicalCondition",
"name": "Métolazone",
"code": {
"@type": "MedicalCode",
"code": "D008788",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.786.830.688"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Trimétrexate",
"alternateName": "Trimetrexate",
"url": "https://questionsmedicales.fr/mesh/D016597",
"about": {
"@type": "MedicalCondition",
"name": "Trimétrexate",
"code": {
"@type": "MedicalCode",
"code": "D016597",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.786.925"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Quinazolines",
"alternateName": "Quinazolines",
"code": {
"@type": "MedicalCode",
"code": "D011799",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Monika Kubacka",
"url": "https://questionsmedicales.fr/author/Monika%20Kubacka",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacodynamics, Faculty of Pharmacy, Medical College, Jagiellonian University, Medyczna 9, 30-688, Kraków, Poland. Electronic address: mfkuback@cyf-kr.edu.pl."
}
},
{
"@type": "Person",
"name": "Magdalena Kotańska",
"url": "https://questionsmedicales.fr/author/Magdalena%20Kota%C5%84ska",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacodynamics, Faculty of Pharmacy, Medical College, Jagiellonian University, Medyczna 9, 30-688, Kraków, Poland."
}
},
{
"@type": "Person",
"name": "Henryk Marona",
"url": "https://questionsmedicales.fr/author/Henryk%20Marona",
"affiliation": {
"@type": "Organization",
"name": "Department of Bioorganic Chemistry, Chair of Organic Chemistry, Faculty of Pharmacy, Medical College, Jagiellonian University, Medyczna 9, 30-688, Kraków, Poland."
}
},
{
"@type": "Person",
"name": "Szczepan Mogilski",
"url": "https://questionsmedicales.fr/author/Szczepan%20Mogilski",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacodynamics, Faculty of Pharmacy, Medical College, Jagiellonian University, Medyczna 9, 30-688, Kraków, Poland."
}
},
{
"@type": "Person",
"name": "Raphaël Bolteau",
"url": "https://questionsmedicales.fr/author/Rapha%C3%ABl%20Bolteau",
"affiliation": {
"@type": "Organization",
"name": "Univ. Lille, Inserm, CHU Lille, U1172, LilNCog - Lille Neuroscience & Cognition, F-59000, Lille, France."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Discovery of Quinazoline-2,4(1",
"datePublished": "2023-10-16",
"url": "https://questionsmedicales.fr/article/37843892",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.jmedchem.3c01152"
}
},
{
"@type": "ScholarlyArticle",
"name": "Novel Quinazoline Derivatives as Highly Effective A2A Adenosine Receptor Antagonists.",
"datePublished": "2024-08-14",
"url": "https://questionsmedicales.fr/article/39202926",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/molecules29163847"
}
},
{
"@type": "ScholarlyArticle",
"name": "2-Substituted quinazolines: Partial agonistic and antagonistic ligands of the constitutive androstane receptor (CAR).",
"datePublished": "2023-07-13",
"url": "https://questionsmedicales.fr/article/37473690",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejmech.2023.115631"
}
},
{
"@type": "ScholarlyArticle",
"name": "Design, synthesis, and structure-activity relationships of a novel class of quinazoline derivatives as coronavirus inhibitors.",
"datePublished": "2023-09-25",
"url": "https://questionsmedicales.fr/article/37813064",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejmech.2023.115831"
}
},
{
"@type": "ScholarlyArticle",
"name": "Design, synthesis, and pharmacological evaluation of quinazoline derivatives as novel and potent pan-JAK inhibitors.",
"datePublished": "2023-08-07",
"url": "https://questionsmedicales.fr/article/37582330",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.bioorg.2023.106765"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérobicycliques",
"item": "https://questionsmedicales.fr/mesh/D006574"
},
{
"@type": "ListItem",
"position": 5,
"name": "Quinazolines",
"item": "https://questionsmedicales.fr/mesh/D011799"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Quinazolines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Quinazolines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Quinazolines",
"description": "Comment diagnostiquer une intoxication aux quinazolines ?\nQuels tests sont utilisés pour détecter les quinazolines ?\nQuels symptômes indiquent une surdose de quinazolines ?\nLes quinazolines sont-elles visibles sur les tests de toxicologie ?\nComment évaluer l'efficacité d'un traitement par quinazolines ?",
"url": "https://questionsmedicales.fr/mesh/D011799#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Quinazolines",
"description": "Quels sont les effets secondaires courants des quinazolines ?\nLes quinazolines provoquent-elles des réactions allergiques ?\nQuels symptômes indiquent une hypersensibilité aux quinazolines ?\nLes quinazolines affectent-elles le système nerveux ?\nQuels signes cliniques sont associés à une surdose de quinazolines ?",
"url": "https://questionsmedicales.fr/mesh/D011799#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Quinazolines",
"description": "Comment prévenir les effets indésirables des quinazolines ?\nLes patients doivent-ils être surveillés lors de l'utilisation de quinazolines ?\nQuelles précautions prendre avant de prescrire des quinazolines ?\nLes femmes enceintes peuvent-elles utiliser des quinazolines ?\nComment informer les patients sur les quinazolines ?",
"url": "https://questionsmedicales.fr/mesh/D011799#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Quinazolines",
"description": "Comment traiter une intoxication aux quinazolines ?\nLes quinazolines sont-elles utilisées en chimiothérapie ?\nQuels médicaments contiennent des quinazolines ?\nComment les quinazolines agissent-elles sur les cellules cancéreuses ?\nY a-t-il des antidotes pour les surdoses de quinazolines ?",
"url": "https://questionsmedicales.fr/mesh/D011799#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Quinazolines",
"description": "Quelles complications peuvent survenir avec les quinazolines ?\nLes quinazolines peuvent-elles causer des problèmes cardiaques ?\nComment gérer les complications liées aux quinazolines ?\nLes quinazolines peuvent-elles affecter la fonction rénale ?\nQuelles sont les complications à long terme des quinazolines ?",
"url": "https://questionsmedicales.fr/mesh/D011799#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Quinazolines",
"description": "Quels facteurs augmentent le risque d'effets indésirables des quinazolines ?\nLes interactions médicamenteuses sont-elles un facteur de risque ?\nLes personnes âgées sont-elles plus à risque avec les quinazolines ?\nLe tabagisme influence-t-il l'efficacité des quinazolines ?\nLes antécédents familiaux de maladies sont-ils un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D011799#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une intoxication aux quinazolines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique médical et des tests de laboratoire spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les quinazolines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des analyses sanguines et urinaires peuvent être effectuées pour détecter les quinazolines."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une surdose de quinazolines ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des nausées, des vertiges et des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Les quinazolines sont-elles visibles sur les tests de toxicologie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines quinazolines peuvent être détectées par des tests de toxicologie spécifiques."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité d'un traitement par quinazolines ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par des critères cliniques et des examens d'imagerie."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants des quinazolines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent des maux de tête, des nausées et des éruptions cutanées."
}
},
{
"@type": "Question",
"name": "Les quinazolines provoquent-elles des réactions allergiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des réactions allergiques peuvent survenir, comme des démangeaisons ou de l'urticaire."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une hypersensibilité aux quinazolines ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des gonflements, des démangeaisons et des difficultés respiratoires peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les quinazolines affectent-elles le système nerveux ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent provoquer des vertiges, des troubles de la coordination et des convulsions."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont associés à une surdose de quinazolines ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent confusion, tachycardie et hypotension."
}
},
{
"@type": "Question",
"name": "Comment prévenir les effets indésirables des quinazolines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est essentiel de suivre les prescriptions médicales et de signaler tout effet indésirable."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils être surveillés lors de l'utilisation de quinazolines ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surveillance régulière est recommandée pour détecter les effets secondaires."
}
},
{
"@type": "Question",
"name": "Quelles précautions prendre avant de prescrire des quinazolines ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évaluer les antécédents médicaux et les allergies du patient est crucial."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes peuvent-elles utiliser des quinazolines ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'utilisation doit être évitée, sauf si les bénéfices l'emportent sur les risques."
}
},
{
"@type": "Question",
"name": "Comment informer les patients sur les quinazolines ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fournir des informations claires sur les effets secondaires et les interactions médicamenteuses."
}
},
{
"@type": "Question",
"name": "Comment traiter une intoxication aux quinazolines ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut l'administration de charbon actif et une surveillance médicale étroite."
}
},
{
"@type": "Question",
"name": "Les quinazolines sont-elles utilisées en chimiothérapie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines quinazolines sont utilisées comme agents chimiothérapeutiques dans le cancer."
}
},
{
"@type": "Question",
"name": "Quels médicaments contiennent des quinazolines ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme le gefitinib et le lapatinib contiennent des quinazolines."
}
},
{
"@type": "Question",
"name": "Comment les quinazolines agissent-elles sur les cellules cancéreuses ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles inhibent des voies de signalisation spécifiques, ralentissant la croissance tumorale."
}
},
{
"@type": "Question",
"name": "Y a-t-il des antidotes pour les surdoses de quinazolines ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas d'antidote spécifique, le traitement est symptomatique."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les quinazolines ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des troubles hépatiques et des réactions cutanées graves peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les quinazolines peuvent-elles causer des problèmes cardiaques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent entraîner des arythmies et d'autres problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées aux quinazolines ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut l'arrêt du médicament et le traitement des symptômes associés."
}
},
{
"@type": "Question",
"name": "Les quinazolines peuvent-elles affecter la fonction rénale ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets néfastes sur la fonction rénale ont été rapportés chez certains patients."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications à long terme des quinazolines ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications à long terme peuvent inclure des troubles métaboliques et des cancers secondaires."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'effets indésirables des quinazolines ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents d'allergies et les maladies hépatiques augmentent le risque d'effets indésirables."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses sont-elles un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines interactions médicamenteuses peuvent augmenter les effets des quinazolines."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque avec les quinazolines ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent être plus sensibles aux effets secondaires des quinazolines."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il l'efficacité des quinazolines ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut réduire l'efficacité des quinazolines en affectant leur métabolisme."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux de maladies sont-ils un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies peuvent augmenter le risque d'effets indésirables."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 28/03/2026
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Department of Pharmacodynamics, Faculty of Pharmacy, Medical College, Jagiellonian University, Medyczna 9, 30-688, Kraków, Poland. Electronic address: mfkuback@cyf-kr.edu.pl.
Publications dans "Quinazolines" :
3 publications dans cette catégorie
Affiliations :
Department of Pharmacodynamics, Faculty of Pharmacy, Medical College, Jagiellonian University, Medyczna 9, 30-688, Kraków, Poland.
Publications dans "Quinazolines" :
3 publications dans cette catégorie
Affiliations :
Department of Bioorganic Chemistry, Chair of Organic Chemistry, Faculty of Pharmacy, Medical College, Jagiellonian University, Medyczna 9, 30-688, Kraków, Poland.
Publications dans "Quinazolines" :
3 publications dans cette catégorie
Affiliations :
Department of Pharmacodynamics, Faculty of Pharmacy, Medical College, Jagiellonian University, Medyczna 9, 30-688, Kraków, Poland.
Publications dans "Quinazolines" :
3 publications dans cette catégorie
Affiliations :
Univ. Lille, Inserm, CHU Lille, U1172, LilNCog - Lille Neuroscience & Cognition, F-59000, Lille, France.
Publications dans "Quinazolines" :
3 publications dans cette catégorie
Affiliations :
Univ. Lille, Inserm, CHU Lille, U1172, LilNCog - Lille Neuroscience & Cognition, F-59000, Lille, France.
Publications dans "Quinazolines" :
3 publications dans cette catégorie
Affiliations :
Univ. Lille, Inserm, CHU Lille, U1172, LilNCog - Lille Neuroscience & Cognition, F-59000, Lille, France.
Publications dans "Quinazolines" :
2 publications dans cette catégorie
Affiliations :
Beijing Key Laboratory of Active Substances Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Publications dans "Quinazolines" :
2 publications dans cette catégorie
Affiliations :
Beijing Key Laboratory of Active Substances Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Publications dans "Quinazolines" :
2 publications dans cette catégorie
Affiliations :
Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Publications dans "Quinazolines" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Publications dans "Quinazolines" :
2 publications dans cette catégorie
Affiliations :
Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Publications dans "Quinazolines" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Publications dans "Quinazolines" :
2 publications dans cette catégorie
Affiliations :
Beijing Key Laboratory of Active Substances Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Publications dans "Quinazolines" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Publications dans "Quinazolines" :
2 publications dans cette catégorie
Affiliations :
Jiangxi Province Key Laboratory of Chemical Biology, College of Chemistry and Chemical Engineering, Jiangxi Normal University, Nanchang, Jiangxi 330022, P. R. China.
Publications dans "Quinazolines" :
2 publications dans cette catégorie
Affiliations :
Jiangxi Province Key Laboratory of Chemical Biology, College of Chemistry and Chemical Engineering, Jiangxi Normal University, Nanchang, Jiangxi 330022, P. R. China.
Publications dans "Quinazolines" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology & Bioinformatics, Volgograd State Medical University, 400001 Volgograd, Russia.
Scientific Center for Innovative Drugs, Volgograd State Medical University, 400087 Volgograd, Russia.
Publications dans "Quinazolines" :
2 publications dans cette catégorie
Affiliations :
Scientific Center for Innovative Drugs, Volgograd State Medical University, 400087 Volgograd, Russia.
Department of Pharmaceutical & Toxicological Chemistry, Volgograd State Medical University, 400001 Volgograd, Russia.
Publications dans "Quinazolines" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology & Bioinformatics, Volgograd State Medical University, 400001 Volgograd, Russia.
Scientific Center for Innovative Drugs, Volgograd State Medical University, 400087 Volgograd, Russia.
Publications dans "Quinazolines" :
PARP-1/2 inhibitors have become an important therapeutic strategy for the treatment of HR-deficient tumors. However, discovery of new inhibitors with an improved and distinct pharmacological file stil...
Following the discovery of 2-(3-methoxyphenyl)-3,4-dihydroquinazoline-4-one and 2-(3-methoxyphenyl)quinazoline-4-thione as potent, but non-specific activators of the human Constitutive Androstane Rece...
There remain great unmet needs to treat coronavirus infections in clinic, and the development of novel antiviral agents is highly demanded. In this work, a phenotypic screening against our in-house co...
Janus kinases (JAKs) play a critical role in modulating the function and expression of inflammatory cytokines related to rheumatoid arthritis (RA). Herein, we report the design, synthesis, and structu...
Serotype coxsackievirus B (CVB) infection has been linked to viral myocarditis, dilated cardiomyopathy, meningitis, and pancreatitis in children and young adults. As of yet, no antiviral drug has been...
This study investigated the cytotoxicity of the target benzo[g]quinazolines (1-16) in the BGM cells line as well as their anti-coxsackievirus B4 activity. Determination of CVB4 titers using a plaque a...
Most of the target benzoquinazolines exhibited antiviral activity, however, compounds 1-3 appeared to be the most effective (reduction percentages of 66.7, 70, and 83.3%, respectively). The binding me...
The anti coxsackievirus B4 activity has resulted, and the top three active benzoquinazolines (1-3) have bonded to and interacted with the constitutive amino acids in the active region of the multi-tar...
Quinazoline derivatives, as an important category of heterocyclic compounds, have received much attention for the design and development of new drugs due to their various pharmacological properties. B...
A novel series of 4-(3-1H-indazolyl)amino quinazoline derivatives were developed as PAK4 inhibitors based on a scaffold hopping strategy. Compounds 27e, 27g, 27i and 27j were found to exhibit potent i...
In this study, new quinazoline-chromene hybrid compounds were synthesized. The cytotoxic effects on cell viability of the hybrid compounds were tested against A549 human lung adenocarcinoma and BEAS-2...
Angiogenesis, the formation of new blood vessels from the existing vasculature, is pivotal in the migration, growth, and differentiation of endothelial cells in normal physiological conditions. In var...